Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.

Genta ItoKazuyoshi KawakamiTakeshi AoyamaTakashi YokokawaMasashi NakamuraMasato OzakaNaoki SasahiraMasayuki HashiguchiHayato KizakiToshihiro HamaSatoko Hori

Published in: PloS one (2021)

Low ANC, high T-Bil, and low CRP may be risk factors for Grade 3/4 neutropenia in patients receiving GnP therapy, even if these laboratory values are within normal reference ranges. Patients with these risk factors should be carefully monitored for adverse events.

Keyphrases

combination therapy
risk factors
chemotherapy induced
early onset
advanced non small cell lung cancer
stem cells
radiation therapy
drug induced